*For medical professionals for reference only
This two issues of "Antipoltaic Coffee Talk" special experts and scholars combined with the latest domestic NST-ACS guide And ESC and ACCs latest studies, share experience experience in ACS anti -thrombus and lipid -lowering therapy.
The most important pathophysiological mechanism of acute coronary syndrome (ACS) includes plaques rupture, plaques erosion and coronary spasm [1].Its plaque rupture or erosion is often accompanied by formation. Time and effective antiphantal anti-thrombus treatment is essential for ACS patients.In addition, abnormal blood lipids play an important role in the occurrence of atherosclerotic hardening cardiovascular disease (ASCVD) and development.Therefore, in the ACS prevention strategy, in addition to the implementation of effective anti -platelet treatment, blood lipid management cannot be ignored.Studies have shown that taking effective anti -platelets and lipid -lowering methods can significantly delay the progress of plaques, stabilize and damaged plaques, and reduce the risk of patients adverse vascular events [1, 2].
With the accumulation of evidence, the Chinese Medical Association Disease Branch organized experts and scholars to compose "non-ST Diagnosis and Treatment Guidelines (2024) "[3] [3] provided new guidance for ACS patients with ACS patients.In addition, this years annual meeting of the American Cardiac Society (ACC) and the European Cardiac Society (ESC) announced a series of ACS related research results, which are anti -thrombus treatment and optimization of anti -thrombus treatment during the Cross -shaped Coronary Invasion Treatment (PCI) perinatal therapy (PCI) surgery. The application of lipid therapy strategy and the application of the new P2Y12 receptor inhibitor in ACS treatment has brought a new perspective, and it also provides more treatment options for clinicians.
Based on this, "Medical Hearts" Cardiovascular Department of Cardiovascular Clinical Diagnosis and Treatment Improving Project "Antiphantal Coffee Talks 68th Issue 68; Issue 69" It will be launched on November 4, 2024 (Monday) 15: 00-16: 30 and November 5, 2024 (Tuesday) 19: 00-20: 30. Professor Liu Fuyuan of the Peoples Hospital, Professor Zeng Qiutang, Affiliated to the Tongji Medical College of Huazhong University of Science and Technology, Professor He Ronghua, Xiaogan City Center Hospital, Professor Li Mingjian, Xiangyang Traditional Chinese Medicine Hospital, Professor Wu Sanwu of Shiyan Peoples Hospital (No. 68), Guangdong Peoples Peoples Professor Yang Junqing, Professor Bian Ning, the First Affiliated Hospital of Jinan University, Professor Chen Guojun, Nanfang Hospital of Southern Medical University, Professor Dong Haojian, Guangdong Provincial Peoples Hospital, and Professor Ding Yuexia, Fifth Hospital of Guangzhou Medical University (No. 69) The ST section raised acute coronary syndrome diagnosis and treatment guidelines (2024) and the latest research results of ACC and ESC, and in -depth discussion of the high -efficiency anti -thrombus and lipid -lowering strategies of ACS patients, in order to help further standardize clinical diagnosis and treatment.
See the poster in the live broadcast schedule,
Please look forward to it!
References:
[1]. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013 May 23;368(21):2004-13.
[2]. Naghavi m, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment 14): 1664-72.
[3]. Chinese Medical Society Cardiovascular Disease Branch, Editorial Committee of China Cardiovascular Disease Magazine. ]. China Cardiovascular Disease Magazine, 2024,52 (6): 615-646.
More exciting content of cardiovascular vascular
Come " Doctor Station Network Page version " Take a look
Wonderful information is waiting for you
* For the reference of medical and health professionals, it is not allowed to forward or share non -medical and health professionals.
